Prot #CCMK389X2201: A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients with Chronic Pulmonary Sarcoidosis

Project: Research project

Project Details

StatusFinished
Effective start/end date10/14/21 → 12/3/24

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CCMK389X2201)